Drugs / Peg-Interferon α
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06368882 Comparator | Jan 2024 → Dec 2028 expected | NAFLD1, chronic hepatitis B virus infection | First Affiliated Hospital of Wenzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peg-Interferon α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06368882 ↗ |
| Route | Subcutaneous | “Peg IFN-α injection was subcutaneously injected 180 μg weekly” NCT06368882 ↗ |